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Abstract
Changes in vascular endothelial growth factor (VEGF) in pulmonary vessels have been described in congenital diaphragmatic
hernia (CDH) and may contribute to the development of pulmonary hypoplasia and hypertension; however, how the expression
of VEGF receptors changes during fetal lung development in CDH is not understood. The aim of this study was to compare
morphological evolution with expression of VEGF receptors, VEGFR1 (Flt-1) and VEGFR2 (Flk-1), in pseudoglandular,
canalicular, and saccular stages of lung development in normal rat fetuses and in fetuses with CDH. Pregnant rats were divided
into four groups (n=20 fetuses each) of four different gestational days (GD) 18.5, 19.5, 20.5, 21.5: external control (EC),
exposed to olive oil (OO), exposed to 100 mg nitrofen, by gavage, without CDH (N-), and exposed to nitrofen with CDH (CDH)
on GD 9.5 (term=22 days). The morphological variables studied were: body weight (BW), total lung weight (TLW), left lung
weight, TLW/BW ratio, total lung volume, and left lung volume. The histometric variables studied were: left lung parenchymal
area density and left lung parenchymal volume. VEGFR1 and VEGFR2 expression were determined by Western blotting. The
data were analyzed using analysis of variance with the Tukey-Kramer post hoc test. CDH frequency was 37% (80/216). All the
morphological and histometric variables were reduced in the N- and CDH groups compared with the controls, and reductions
were more pronounced in the CDH group (P,0.05) and more evident on GD 20.5 and GD 21.5. Similar results were observed
for VEGFR1 and VEGFR2 expression. We conclude that N- and CDH fetuses showed primary pulmonary hypoplasia, with a
decrease in VEGFR1 and VEGFR2 expression.
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Introduction
Congenital diaphragmatic hernia (CDH) occurs in
approximately 1 in 2500 live births and still causes high
neonatal mortality as a consequence of pulmonary
hypoplasia and persistent pulmonary hypertension (1).
Vascular endothelial growth factor (VEGF) and its recep-
tors, VEGFR1 (Flt-1) and VEGFR2 (Flk-1), participate in
angiogenesis by stimulating proliferation of new vessels
and by offering a background for airway branching (2,3).
VEGFR2 signaling produces various cellular
responses, including mitogenic and survival signals for
endothelial cells and their precursors (4,5), therefore
silencing the VEGFR2 gene reduces or suppresses of
vasculogenesis in rats (6,7). VEGFR1 participates in the
development of blood vessels by negatively modulating
endothelial cell division through a restriction of VEGFR2
signaling (8,9). Knockout mice for the VEGFR1 gene did
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not survive to the end of pregnancy due to hypertrophy
and disorganization of the vascular bed (10).
The changes in pulmonary vessels and serum levels
of VEGF described in CDH likely contribute to the
development of pulmonary hypoplasia and hypertension
(11). VEGF participates in pulmonary development and
surfactant production and induces conversion of glycogen
into surfactant in type II pneumocytes (12); however,
there are a limited number of studies on VEGF receptors.
Changes in the levels of VEGF and its receptors cause a
disturbance in angiogenesis, leading to a detrimental
remodeling of small arteries. Studies of the expression of
VEGF in CDH have produced conflicting results.
One study showed that VEGF increased in the
nitrofen-induced CDH rat model with pulmonary hyperten-
sion; however, several other studies showed that VEGF
decreased in the same model (13,14). Considering that
not only VEGF but also the VEGF receptors may be
involved in the development of pulmonary hypertension,
our aim was to examine the expression of these receptors
in the pseudoglandular, canalicular, and saccular stages
of lung development of normal rat fetuses and of fetuses
with CDH.
Material and Methods
Experimental protocols were reviewed and approved
by the Animal Experimentation Committee of the
Faculdade de Medicina de Ribeira˜o Preto, Universidade
de Sa˜o Paulo (FMRP-USP; #043/2011).
Sprague-Dawley rats (±250 g) were mated during the
night cycle and females were checked on the following day
for a sperm-positive vaginal smear. The day of plugging
was defined as gestational day 0 (term=22 days). A total
of 52 pregnant rats were studied in four groups: 10 external
control (EC), 10 exposed to olive oil (OO), and 32 rats
exposed to nitrofen that did not develop CDH (N-) or that
did develop CDH (CDH).
Nitrofen administration
To induce CDH, timed-pregnant rats were given
100 mg nitrofen (2,4-dichloro-4-nitrodiphenyl ether,
Maybridge1; UK) dissolved in 1 mL olive oil on gestational
day (GD) 9.5, by gavage. The placebo group received
1 mL olive oil without nitrofen at the same gestational age
(OO group). This dose of nitrofen has been shown to cause
left-sided CDH in 24% of the litter (15).
Model and experimental groups
All four groups of fetuses (EC, OO, N-, and CDH) were
harvested at 18.5, 19.5, 20.5, or 21.5 GD (20 fetuses per
group for each gestational day, giving a total of 80 fetuses
in each group). The pregnant female rats were anesthe-
tized on the specific day of gestation using 50 mg/mL
ketamine (175 mg/kg; Ketamina1, Pfizer do Brasil Ltda.,
Brazil) in conjunction with 10 mg/mL xylazine (2.5 mg/kg;
Rompum1, Bayer do Brasil Ltda., Brazil), and the fetuses
were collected through a median maternal laparotomy
and hysterotomy.
Morphological measurements
The fetuses were weighed [body weight (BW)] and
dissected. Their left lung weight (LLW) and total lung
weight (TLW) were measured, and the lung-to-body weight
ratio (TLW/BW) was determined as were the total lung
volume [V(lu)], left lung volume [V(llu)], left lung parenchy-
mal area density [AA(pa/llu)], and left lung parenchymal
volume [V(pal)].
Histological analysis
The left lungs were fixed, washed in phosphate buffer,
and processed following a protocol for paraffin embed-
ding. The histological samples were sectioned (5 mm
thick), and sections were deparaffinized and stained with
hematoxylin-eosin, and examined by light microscopy.
Obtaining images for analysis
Images from the histological sections of the left lung
were obtained at 2006 magnification. We analyzed 50
images per animal, from five animals per group in each
endpoint, totaling 200 images for each group. For
stereological analysis, we used a grid with 100 points
generated by the Image-Pro Plus software, version
4.1.0.0 (Media Cybernetics, USA).
Stereological calculations
Lung volume [V(lu)]. The total V(lu) was calculated
using Archimedes’ principle. The volume of the lung was
determined from the volume of water displaced when it
was suspended by a wire in a container of water (and not
touching the walls or bottom of the container), as
described by Scherle (16) and Howard and Reed (17).
Volume of parenchyma [V(pa)]. The density of the
parenchymal area [AA(pa/lu)] was estimated by dividing
the number of points that fall in the pa, excluding large
bronchi and large blood vessels, by the number of points
that fall within the lung as a whole (lu), excluding the
airspace, at 2006 magnification [AA(pa/lu)=pa/lu]. The
volume of the left lung parenchyma [V(pal)] was obtained
by multiplying the left lung volume [V(llu)] by the AA(pa/
llu), according to Papadakis et al. (18) [V(pal)=V(llu)
6AA(pa/llu)], utilizing the Image Pro Plus 6.0 software
(Media Cybernetics).
Western blotting
Whole lungs from 6 animals per group were homog-
enized in 1 mL extraction buffer containing 100 mM Tris,
pH 7.4, 100 mM sodium pyrophosphate, 100 mM sodium
fluoride, 10 mM EDTA, 10 mM sodium vanadate, 2 mM
phenylmethylsulfonyl fluoride, 0.1 mg/mL aprotinin, and
1% Triton-X 100 at 46C with a tissue homogenizer (Tecnal,
Brazil) operated at maximum speed for 30 s. The extracts
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were centrifuged at 9000 g at 46C in a Mikro 200R
centrifuge (Hettich, Germany) for 30 min to remove
insoluble material, and the supernatants of these tissues
were used for protein quantification using the Bradford
method. Then, 90 mg protein was denatured, run on SDS-
PAGE, and transferred to nitrocellulose membranes in
two stages for 1 h each at 120 V. The membranes were
blocked for 1 h in 5% milk in 0.01 M PBS, pH 7.4, and
incubated with anti-VEGFR1 (sc-316, Santa Cruz
Biotechnology, USA) or anti-VEGFR2 (sc-6251, Santa
Cruz Biotechnology) diluted 1:200 in 5% milk in 0.01 M
PBS, pH 7.4, for 2 h at room temperature. They were then
incubated with biotin-conjugated anti-rabbit IgG (1:10,000
in 1% BSA) for 2 h at room temperature for VEGFR1 and
with biotin-conjugated anti-mouse IgG (1:5000 in 1% BSA)
for 2 h for VEGFR2. Finally, the membranes were probed
with the Supersignal Chemiluminescence kit (Pierce,
USA), exposed to radiographic films for 7 min (Kodak,
USA), and developed.
Statistical analysis
Morphological data were compared by analysis of
variance and by the Tukey-Kramer post hoc test using the
Statistical Analysis System for Windows (SAS 8.01, SAS
Institute, USA). Statistical significance was considered to
be P,0.05.
Results
Morphological
Examination of the nitrofen-exposed fetuses showed that
37% (80/216) had CDH. All the morphological and histo-
metric variables showed reductions in the N- and CDH
groups, compared with the controls (EC and OO groups),
which were more pronounced in those with CDH). All fetuses
exposed to nitrofen (N- and CDH groups) had decreased
BW, TLW, LLW, TLW/BW, V(lu), V(llu), AA(pa/llu), and V(pal)
compared with non-exposed fetuses (EC and OO groups,
P,0.05). Fetuses with CDH showed decreased TLW, LLW,
TLW/BW, V(lu), V(llu), AA(pa/llu), and V(pal) compared with
N- fetuses at GD 19.5, 20.5, and 21.5 (P,0.001), but there
was no difference at GD 18.5 (see Table 1 and Figure 1).
Histology
On GD 18.5, 19.5, 20.5, and 21.5, the development of
an airspace in the EC, OO, and N- groups was observed.
However, the opposite occurred in the CDH group, with
decreased airspace and pulmonary hypoplasia increas-
ingly evident at the later gestational ages (Figure 2).
Western blotting
Our results demonstrated that the protein expression
levels of VEGFR1 and VEGFR2 in these four development
Table 1. Morphological variables of fetuses.
Group/GD BW TLW LLW TLW/BW V(lu) V(llu) AA(pa/llu) V(pal)
EC
18.5 237 ± 19 80 ± 17 29 ± 6 0.034 ± 0.006 78 ± 16 27 ± 6 0.77 ± 0.05 2074 ± 132
19.5 391 ± 40 126 ± 11 43 ± 6 0.033 ± 0.003 123 ± 11 41 ± 6 0.66 ± 0.06 2709 ± 265
20.5 555 ± 41 147 ± 33 51 ± 11 0.027 ± 0.007 143 ± 34 49 ± 13 0.63 ± 0.06 3132 ± 285
21.5 647 ± 48 145 ± 17 50 ± 7 0.023 ± 0.003 143 ± 16 48 ± 6 0.49 ± 0.10 2348 ± 490
OO
18.5 244 ± 13 89 ± 9 29 ± 3 0.037 ± 0.003 86 ± 10 28 ± 3 0.88 ± 0.06ac 2454 ± 175ac
19.5 364 ± 32a 130 ± 17 44 ± 6 0.036 ± 0.003a 127 ± 17 40 ± 11 0.75 ± 0.05ac 3072 ± 203ac
20.5 503 ± 43a 140 ± 15 48 ± 6 0.028 ± 0.003 137 ± 15 46 ± 6 0.63 ± 0.05c 2906 ± 250ac
21.5 580 ± 29a 144 ± 12 49 ± 5 0.025 ± 0.002a 140 ± 12 47 ± 5 0.58 ± 0.07ac 2704 ± 314a
N-
18.5 211 ± 17ab 63 ± 11ab 23 ± 4ab 0.030 ± 0.004ab 59 ± 10ab 21 ± 4ab 0.80 ± 0.05ab 1671 ± 104ab
19.5 342 ± 20a 105 ± 15ab 38 ± 5ab 0.030 ± 0.004ab 101 ± 15ab 36 ± 6 0.67 ± 0.05b 2432 ± 197a
20.5 457 ± 39ab 104 ± 16ab 38 ± 7ab 0.023 ± 0.003ab 100 ± 16ab 36 ± 6ab 0.53 ± 0.06ab 2416 ± 195ab
21.5 561 ± 55 101 ± 19ab 38 ± 6ab 0.018 ± 0.003ab 97 ± 19ab 36 ± 6ab 0.55 ± 0.10b 2091 ± 261b
CDH
18.5 213 ± 20ab 59 ± 8ab 20 ± 3ab 0.028 ± 0.005ab 56 ± 8abc 19 ± 3ab 0.85 ± 0.05ac 1615 ± 86ac
19.5 310 ± 25abc 77 ± 14abc 25 ± 6abc 0.024 ± 0.001abc 74 ± 15abc 24 ± 7abc 0.80 ± 0.05abc 1925 ± 118abc
20.5 451 ± 36ab 80 ± 12abc 25 ± 5abc 0.018 ± 0.002abc 76 ± 12abc 23 ± 6abc 0.80 ± 0.05abc 1928 ± 125abc
21.5 541 ± 51 78 ± 13abc 25 ± 6abc 0.014 ± 0.002abc 76 ± 14abc 23 ± 5abc 0.78 ± 0.05ac 1804 ± 113abc
Data are reported as means±SD. GD: gestational days; BW: body weight; TLW: total lung weight; LLW: left lung weight; TLW/BW:
TLW/BW ratio; V(lu): total lung volume; V(llu): left lung volume; AA(pa/lu): left lung parenchymal area density; V(pal): left lung
parenchymal volume; EC: external controls; OO: exposed to olive oil; N-: exposed to nitrofen without CDH; CDH: exposed to nitrofen
with CDH; aP,0.05 compared with EC group; bP,0.05 compared with OO group; cP,0.05 compared with N- group.
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Figure 1. Evolution at 18.5, 19.5, 20.5, and 21.5 gestational days of: A, body weight (BW) and total lung weight (TLW); B, left lung
weight (LLW) and TLW/BW ratio; C, total lung volume [V(lu)] and left lung volume [V(llu)]; D, left lung parenchymal area density [AA(pa/
llu)] and left lung parenchyma volume [V(pal)]. EC: external control; OO: exposed to olive oil; N-: exposed to nitrofen without CDH;
CDH: exposed to nitrofen with CDH.
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phases were lower in the CDH group than in the N-, EC,
and OO groups (P,0.001; see Figure 3).
Discussion
The rat model of CDH pioneered by Iritani (19) allowed
reproduction of all components of the malformation by
administration of nitrofen (2,4-dichloro-49-nitrodiphenyl
ether) to pregnant rats during the appropriate embryologic
window. The nature of lung hypoplasia associated with
CDH has been investigated in this model, and a dual-hit
mechanism involving primary maldevelopment and sec-
ondary compressive changes is currently accepted (20-
22).
Although we did not address the early (embryonic)
stage of lung development, our results are consistent with
those of Kluth et al. (15) in terms of the proportion of CDH
in exposed fetuses (37 vs 24%) and with those of Pringle
(23) in terms of the timing of the pseudoglandular (GD
18.5), canalicular (GD 18.5, 19.5 and 20.5), and saccular
(GD 20.5 and 21.5) stages of lung development.
We found that BW, TLW, LLW, V(lu), and V(llu)
increased progressively during fetal development,
whereas TLW/BW decreased in all groups, particularly
in those with CDH (P,0.001), in agreement with previous
reports (22). Recently, we published two studies that
showed similar results in BW, TLW and LLW, but we have
not calculated the lung volume at 21.5 days (24,25). The
V(pal) in fetuses exposed to nitrofen was smaller than for
those in the EC and OO groups, indicating that the
primary lung injury caused by nitrofen occurred early,
evidenced by similar V(pal) in N- and CDH groups. The
V(llu) and the LLW were also similar in the two groups
exposed to nitrofen, possibly due to impaired airspace
development because of the intrathoracic presence of
abdominal organs. This is more evident in fetuses with
CDH in comparison to all other groups (P,0.05).
We observed that the EC and OO groups were very
similar when comparing variables during the same
gestational period. We believe that small differences
between these groups may be related to the stress of
gavaging olive oil to the pregnant rats, or to the nutritional
supply of extra fat because the olive oil is not part of
normal diet of these animals. Moreover, none of the
authors who used the nitrofen model have shown a
comparison with an EC group, perhaps because they
believe that the OO group is the only real control.
VEGF is a key stimulator of angiogenesis that acts to
induce mitosis and migration of vascular endothelial cells. In
addition to promoting angiogenesis and neovascularization,
Figure 2. Photomicrographs of fetal lungs from the external control (EC), exposed to olive oil (OO), exposed to nitrofen without CDH
(N-), and exposed to nitrofen with congenital diaphragmatic hernia (CDH) groups at gestational days 18.5, 19.5, 20.5, and 21.5. There
was a decrease in the airspace in panels H, L, and P, demonstrating pulmonary hypoplasia in the CDH group at later gestational ages.
H&E staining, bars: 50 mm.
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it is also a survival factor for newly formed blood
vessels (26-28). The vessels’ receptors, VEGFR1 (Flt-1)
and VEGFR2 (Flk-1) in rats and KDR in humans, have
tyrosine kinase activity and function in the opening of
Ca2+ channels located in the membranes of endothelial
cells (29-31).
Among the various effects of VEGF in vascular and
epithelial cells, the temporal-spatial expression of VEGF
has been suggested to be important, not only for the
formation of capillaries but also for controlling bronchial
and alveolar growth (32-34). Changes in VEGF and its
receptors cause a disturbance of angiogenesis, leading to
a detrimental remodeling of small arteries. Tenbrinck et al.
(35) showed that, in CDH, the arterioles on the level of
respiratory bronchioles and larger airways had an
increased wall thickness (muscularization) that extends
into the peripheral pulmonary artery.
The level of VEGF is increased in primary pulmonary
hypertension of the newborn (PPHN), but this increase
appears to result from hypoxia in lung tissue (due to
pulmonary hypertension and lower blood flow) rather than
hypertension being due to increased VEGF levels. Thus,
the VEGF increase is a consequence of the pulmonary
hypertension and not the cause. In this process, a
derangement in angiogenesis occurs and the resulting
increase in VEGF might compensate for this problem and
produce more blood vessels and blood flow, but this
mechanism worsens the situation because the vessels are
formed in a disorganized fashion (36). Although the
mechanism of PPHN is not the same because in CDH
the hypertension is secondary to anatomical changes in the
pulmonary vasculature before birth, the reduced flow could
lead to a final picture similar to PPHN.
VEGF increased in CDH in just one study (13), and
others showed that VEGF decreased in the nitrofen model
(14). There is no consensus as to whether VEGF
increases or decreases in this model. Shehata et al.
(37) found increased VEGF expression in the lungs of
newborns with CDH, who died of severe pulmonary
hypertension. Oue et al. (38) reported that VEGF
increased, but it could not be excluded that this increase
resulted from nitrofen’s own toxic action. Okazaki et al.
(11) found that VEGF expression was reduced in CDH
and suggested that the mechanisms involved in its
receptors could contribute to increase pulmonary hyper-
tension in the disease. Chang et al. (14) found decreased
Figure 3. Evolution of vascular endothelial growth factor receptors (VEGFR1 and VEGFR2) at 18.5, 19.5, 20.5, and 21.5 days of
gestation. EC: external control; OO: exposed to olive oil; N-: exposed to nitrofen without CDH; CDH: exposed to nitrofen with CDH.
**P,0.001 (analysis of variance with Tukey-Kramer post hoc test).
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VEGF, and Hara et al. (39) found, in fetal rats, that VEGF
increased in lung tissue after performing a tracheal
occlusion. We previously reported that VEGF expression
decreased in CDH, but after performing a tracheal
occlusion with the use of corticosteroids, VEGF expres-
sion increased (24).
Similar to our previous results for VEGF (38), the
levels of VEGFR1 and VEGFR2 in pseudoglandular,
canalicular, and saccular phases of lung development
decreased in the nitrofen group relative to the EC and OO
groups, with an even lower expression in CDH fetuses
(P,0.001).
VEGFR2 is expressed in the early stages of lung
development, whereas VEGFR1 expression increases in
the later stages of development. Thus, it is believed that
VEGFR2 affects the activation of angiogenesis, while
VEGFR1 functions in the maturation and integrity of the
vessel wall. Due to its high affinity for VEGF, but lower
tyrosine kinase activity, VEGFR1 has been implicated in
the sequestration of VEGF, decreasing its availability to
bind VEGFR2, thus acting in the resolution of the
angiogenesis phase (8,40). There is a correlation between
high levels of VEGF and fetal lung maturation. Hypoxia of
lung tissues activates the HIF-2a gene, inducing the
production of VEGF that appears to act on type II
pneumocytes through tyrosine kinase receptors (Flt-1
and Flk-1) and increases the production of surfactant.
VEGF-deficient mice exposed to intrauterine anti-
VEGF receptor (Flk-1) antibodies present respiratory
distress syndrome, due to surfactant deficiency.
Intrauterine application or intratracheal postnatal instilla-
tion of VEGF stimulates surfactant production and may
protect against respiratory distress syndrome (12). We
found that there is negative modulation in the evolution of
the expression of VEGF receptors, and it is noted that as
VEGFR1 tends to decrease during these stages,
VEGFR2 tends to increase. This result is always more
evident on CDH fetuses, as previously reported (8,9).
This decrease in both receptors may be explained by
the lung immaturity that results in CDH and also because
of a toxic component of the herbicide that might interfere
in the model, as both VEGF receptors decreased
regardless of pulmonary hypoplasia being primary or
secondary. Although a toxic component in the nitrofen
group may exist, the CDH lungs had lower concentrations
of VEGF receptors than all other groups. We believe that
there is a synergy between increased VEGF and
VEGFR1 and VEGFR2 in CDH, which may have clinical
implications in compensating for the existing lung hypo-
plasia with CDH.
Therefore, the decrease in VEGFR1 and VEGFR2 in
the CDH rat model may suggest that these proteins are
involved in the genesis of vascular growth and may
correlate with pulmonary hypoplasia. This information
may lead to new studies involving the mechanism of lung
angiogenesis in CDH and possible treatment of pulmo-
nary hypertension in the neonatal period.
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